ID

44514

Description

Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma); ODM derived from: https://clinicaltrials.gov/show/NCT01658878

Lien

https://clinicaltrials.gov/show/NCT01658878

Mots-clés

Versions (2)
  1. 20/02/2020 20/02/2020 -
  2. 27/09/2021 27/09/2021 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

27 septembre 2021

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Hepatocellular Carcinoma NCT01658878

Anglais

Eligibility Hepatocellular Carcinoma NCT01658878

1 Formulaires  
Criteria
Description

Criteria

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects of 18 years or older (men and women) with histological confirmation of advanced hepatocellular carcinoma
Description

Age | Liver carcinoma Advanced

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C2239176
UMLS CUI [2,2]
C0205179
eastern cooperative oncology group (ecog) performance status of 0 to 1
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
for the dose escalation cohorts (uninfected, hcv-infected, and hbv-infected): subjects must have progressive disease following or be intolerant of at least one line of systemic therapy or refuse sorafenib treatment
Description

Dose Escalation Cohort | Infection Absent | Hepatitis C | Hepatitis B | Progressive Disease | Intolerance Systemic therapy Quantity | Sorafenib Refused

Type de données

boolean

Alias
UMLS CUI [1,1]
C3816728
UMLS CUI [1,2]
C0599755
UMLS CUI [2,1]
C3714514
UMLS CUI [2,2]
C0332197
UMLS CUI [3]
C0019196
UMLS CUI [4]
C0019163
UMLS CUI [5]
C1335499
UMLS CUI [6,1]
C0231199
UMLS CUI [6,2]
C1515119
UMLS CUI [6,3]
C1265611
UMLS CUI [7,1]
C1516119
UMLS CUI [7,2]
C1705116
for the uninfected sorafenib naive or intolerant hcc expansion cohort, subjects must either never have received sorafenib treatment or were intolerant to sorafenib therapy
Description

Infection Absent | Sorafenib Absent | Intolerance to Sorafenib | Liver carcinoma Expansion

Type de données

boolean

Alias
UMLS CUI [1,1]
C3714514
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C1516119
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C1744706
UMLS CUI [3,2]
C1516119
UMLS CUI [4,1]
C2239176
UMLS CUI [4,2]
C1519678
for the uninfected sorafenib failure hcc expansion cohort, subjects must have had documented radiographic or symptomatic progression during or after sorafenib therapy
Description

Infection Absent | Sorafenib failed | Liver carcinoma Expansion | Disease Progression Radiography | Disease Progression Symptomatic

Type de données

boolean

Alias
UMLS CUI [1,1]
C3714514
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C1516119
UMLS CUI [2,2]
C0231175
UMLS CUI [3,1]
C2239176
UMLS CUI [3,2]
C1519678
UMLS CUI [4,1]
C0242656
UMLS CUI [4,2]
C0043299
UMLS CUI [5,1]
C0242656
UMLS CUI [5,2]
C0231220
dose escalation phase: child-pugh score of 7 points or less, i.e., child-pugh a or child pugh b7
Description

Dose Escalation Phase | Child-Pugh Score | Child-Pugh Classification

Type de données

boolean

Alias
UMLS CUI [1,1]
C3816728
UMLS CUI [1,2]
C1710475
UMLS CUI [2]
C4055253
UMLS CUI [3]
C4050412
expansion phase: child-pugh score of 6 points or less, i.e., child-pugh a
Description

Expansion Phase | Child-Pugh Score | Child-Pugh Classification

Type de données

boolean

Alias
UMLS CUI [1,1]
C1519678
UMLS CUI [1,2]
C1710475
UMLS CUI [2]
C4055253
UMLS CUI [3]
C4050412
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with brain metasteses
Description

Metastatic malignant neoplasm to brain

Type de données

boolean

Alias
UMLS CUI [1]
C0220650
any prior or current clinically significant ascites as measured by physical examination and that requires active parancentesis for control
Description

Ascites Physical Examination | Paracentesis Required

Type de données

boolean

Alias
UMLS CUI [1,1]
C0003962
UMLS CUI [1,2]
C0031809
UMLS CUI [2,1]
C0034115
UMLS CUI [2,2]
C1514873
any history of clinically meaningful variceal bleeding within the last three months
Description

Bleeding varices

Type de données

boolean

Alias
UMLS CUI [1]
C0333106
active coinfection with both hepatitis b and c
Description

HBV coinfection | HCV coinfection

Type de données

boolean

Alias
UMLS CUI [1]
C2242656
UMLS CUI [2]
C1698259
hepatitis d infection in subjects with hepatitis b
Description

Hepatitis D Infection In addition to Hepatitis B

Type de données

boolean

Alias
UMLS CUI [1,1]
C0011226
UMLS CUI [1,2]
C0332287
UMLS CUI [1,3]
C0019163
Retour au début de la page

Similar models

Eligibility Hepatocellular Carcinoma NCT01658878

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Item Group
C1512693 (UMLS CUI)
Age | Liver carcinoma Advanced
Item
subjects of 18 years or older (men and women) with histological confirmation of advanced hepatocellular carcinoma
boolean
C0001779 (UMLS CUI [1])
C2239176 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 to 1
boolean
C1520224 (UMLS CUI [1])
Dose Escalation Cohort | Infection Absent | Hepatitis C | Hepatitis B | Progressive Disease | Intolerance Systemic therapy Quantity | Sorafenib Refused
Item
for the dose escalation cohorts (uninfected, hcv-infected, and hbv-infected): subjects must have progressive disease following or be intolerant of at least one line of systemic therapy or refuse sorafenib treatment
boolean
C3816728 (UMLS CUI [1,1])
C0599755 (UMLS CUI [1,2])
C3714514 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0019196 (UMLS CUI [3])
C0019163 (UMLS CUI [4])
C1335499 (UMLS CUI [5])
C0231199 (UMLS CUI [6,1])
C1515119 (UMLS CUI [6,2])
C1265611 (UMLS CUI [6,3])
C1516119 (UMLS CUI [7,1])
C1705116 (UMLS CUI [7,2])
Infection Absent | Sorafenib Absent | Intolerance to Sorafenib | Liver carcinoma Expansion
Item
for the uninfected sorafenib naive or intolerant hcc expansion cohort, subjects must either never have received sorafenib treatment or were intolerant to sorafenib therapy
boolean
C3714514 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1516119 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C1516119 (UMLS CUI [3,2])
C2239176 (UMLS CUI [4,1])
C1519678 (UMLS CUI [4,2])
Infection Absent | Sorafenib failed | Liver carcinoma Expansion | Disease Progression Radiography | Disease Progression Symptomatic
Item
for the uninfected sorafenib failure hcc expansion cohort, subjects must have had documented radiographic or symptomatic progression during or after sorafenib therapy
boolean
C3714514 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1516119 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C2239176 (UMLS CUI [3,1])
C1519678 (UMLS CUI [3,2])
C0242656 (UMLS CUI [4,1])
C0043299 (UMLS CUI [4,2])
C0242656 (UMLS CUI [5,1])
C0231220 (UMLS CUI [5,2])
Dose Escalation Phase | Child-Pugh Score | Child-Pugh Classification
Item
dose escalation phase: child-pugh score of 7 points or less, i.e., child-pugh a or child pugh b7
boolean
C3816728 (UMLS CUI [1,1])
C1710475 (UMLS CUI [1,2])
C4055253 (UMLS CUI [2])
C4050412 (UMLS CUI [3])
Expansion Phase | Child-Pugh Score | Child-Pugh Classification
Item
expansion phase: child-pugh score of 6 points or less, i.e., child-pugh a
boolean
C1519678 (UMLS CUI [1,1])
C1710475 (UMLS CUI [1,2])
C4055253 (UMLS CUI [2])
C4050412 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Metastatic malignant neoplasm to brain
Item
subjects with brain metasteses
boolean
C0220650 (UMLS CUI [1])
Ascites Physical Examination | Paracentesis Required
Item
any prior or current clinically significant ascites as measured by physical examination and that requires active parancentesis for control
boolean
C0003962 (UMLS CUI [1,1])
C0031809 (UMLS CUI [1,2])
C0034115 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
Bleeding varices
Item
any history of clinically meaningful variceal bleeding within the last three months
boolean
C0333106 (UMLS CUI [1])
HBV coinfection | HCV coinfection
Item
active coinfection with both hepatitis b and c
boolean
C2242656 (UMLS CUI [1])
C1698259 (UMLS CUI [2])
Hepatitis D Infection In addition to Hepatitis B
Item
hepatitis d infection in subjects with hepatitis b
boolean
C0011226 (UMLS CUI [1,1])
C0332287 (UMLS CUI [1,2])
C0019163 (UMLS CUI [1,3])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial